Background
==========

Medication-overuse headache (MOH) is a chronic, secondary headache caused by excessive intake of symptomatic medications for an underlying headache, most often tension-type headache or migraine. Previously, elevated calcitonin-gene-related peptide (CGRP) levels were found in migraine patients increasing with migraine frequency and in animal MOH models.

Aim
===

To test whether MOH patients have increased CGRP levels before withdrawal therapy compared with healthy volunteers, and further, if the CGRP level would normalize after withdrawal in parallel with the headache-frequency decrease.

Methods
=======

Blood samples from 16 MOH patients before and 6 months after withdrawal start and from 30 healthy volunteers of matching sex and age were analyzed. CGRP concentrations were determined by radioimmunoassay using antibody AB4-2905 and α-CGRP as calibrator. Free and antibody-bound tracer were separated by Sac-Cel separation. The analyses were done blinded to subject group.

Results
=======

Median CGRP concentration was 44.4 pmol/L in MOH patients before withdrawal and 43.8 pmol/L in healthy volunteers (p=0.72). After withdrawal, median CGRP-concentration reduction was 2.1% (p=0.76). Median headache-frequency reduction was 42.5%; from 25 days/month to 12 days/month. Female patients tended to have higher CGRP levels than male patients; 50.6 vs 39.6 pmol/L (p=0.38). We were not able to detect any differences in CGRP concentration according to type of drug overused, in relation to underlying headache type, or to reduction in headache frequency.

Conclusions
===========

No change in CGRP was detected despite dramatic reduction in headache frequency after detoxification of MOH patients. Thus, our results do not support the notion that CGRP is involved in MOH.
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